Jump to content

Julphar: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
added a reference
No edit summary
Tag: adding email address
Line 1: Line 1:
{{Infobox company
{{Infobox company|
company_name = Gulf Pharmaceutical Industries (Julphar) |
|company_name = Julphar
|company_logo = [[File:Julphar-logo.jpg‎|122 × 80 pixels|Gulf Pharmaceutical Industries (Julphar) corporate logo]]
company_logo = [[File:Julphar-logo.jpg‎|122 × 80 pixels|Gulf Pharmaceutical Industries (Julphar) corporate logo]] |
|company_type = Public shareholding company
company_type = [[Public shareholding company|Public]] |
company_slogan = Well Positioned To Meet Tomorrow’s Challenges|
|company_slogan = ''Working together for a better health''
|foundation = 1980
foundation = 1980 |
|location = [[Ras Al Khaimah]], [[United Arab Emirates]]
location = [[Ras Al Khaimah|RAK]], [[United Arab Emirates|UAE]] |
|key_people = [[Sheikh Faisal Bin Saqar Al Qasimi]] ([[Chairman of the Board]])<br/> Dr. Ayman Ahmed Sahli ([[General Manager]])
key_people = '''Sheikh Faisal bin Saqr Al Qasimi ''' [[Chairman of the Board]]<br/> '''Dr. Ayman Ahmed Sahli''' Chief Executive Officer's| CEO|
|num_employees = circa 2350
num_employees = circa 1740 |
|industry = [[Pharmaceutical]]
industry = [[Pharmaceutical]]|
|products = Julphar manufacture and sell more than 423 pharmaceutical products<ref name = AnnualReport2009 >Annual Report 2009 [http://julphar.net/Products/English%20annual%20report%202009.pdf]</ref>
products = Julphar manufacture and sell more than 423 Products |
|revenue = {{profit}} [[United Arab Emirates Dirham|AED]] 762,041 Thousands <small>(2009)</small><ref name="AnnualReport2009"/>
revenue = {{profit}} [[United Arab Emirates Dirham|AED]] 1,024.1 Billion <small>(''2011'')</small>|
|operating_income = {{profit}} [[United Arab Emirates Dirham|AED]] 148,452 Thousands <small>(2009)</small><ref name= AnnualReport2009/>
operating_income = {{profit}} [[United Arab Emirates Dirham|AED]] 200.0 Million <small>(''2011'')</small>|
|net_income = {{profit}} [[United Arab Emirates Dirham|AED]] 122,518 Thousands <small>(2009)</small><ref name= AnnualReport2009/>
net_income = {{profit}} [[United Arab Emirates Dirham|AED]] 170.2 Million <small>(''2011'')</small>|
|website = [http://www.Julphar.net/ www.Julphar.net]
}}
'''Julphar''' is a public shareholding company based in the Emirate of [[Ras Al Khaimah]], [[United Arab Emirates]]. It is engaged in the manufacture of pharmaceutical products that address a range of therapeutic segments.<ref name="ab20120429">{{cite news
|url=http://www.arabianbusiness.com/hh-sheikh-faisal-bin-saqr-al-qasimi-interview-julphar-455510.html
|title=HH Sheikh Faisal Bin Saqr Al Qasimi interview: Julphar
|last=Attwood
|first=Edward
|date=April 29, 2012
|publisher=ArabianBusiness.com
|accessdate=30 April 2012}}</ref>


homepage = [http://www.julphar.net www.julphar.net] |}}
==History==

The Company was established in 1980 under the guidance of H.H.Sheikh [[Saqr bin Mohammad al-Qassimi]] , the Ruler of Ras Al Khaimah.<ref name=history>[http://julphar.net/Vision%20of%20Incorporation.htm Company Profile]</ref>
==About==
'''Julphar (Gulf Pharmaceutical Industries)''' is a public shareholding pharmaceutical company based in Ras Al Khaimah, United Arab Emirates. It was established in 1980 under H.H Sheikh Saqr Bin Mohammed Al Qasimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents. With 3537 products registered (as of February 20, 2012), it is recognized as one of the largest pharmaceutical manufacturers of generic drugs in the Middle East.
Julphar manages a diverse portfolio of therapeutic products which targets a large range of major pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology. (see Products) One of Julphar’s strategic products include Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. Cosmetic scar therapy is a lucrative business worldwide and MEBO Scar follows the success of MEBO, a widely distributed wound healing product. The release of MEBO Scar will help patients with both functional and cosmetic problems caused by scarring and improve their quality of life.<ref>http://www.ameinfo.com/292183.html</ref>

In 2012, Julphar will become the only company in the Middle East and North Africa Region to locally produce r- DNA, the raw material used to make insulin. Julphar Diabetes – a division of Julphar that will manage the manufacturing and commercialization the company’s diabetes products, has the facility capabilities to produce approximately 40 million vials of insulin per year. This makes Julphar the 5th largest producer of insulin in the world, and the only one in the Middle East. In 2011, Julphar signed a partnership with International Diabetes Federation (IDF), ensuring IDF has a key partner in the Middle East region in the fight against diabetes and in their efforts to promote better diabetes care, management and education. Diabetes rates in the MENA are amongst the highest in the world. IDF estimates that in <ref>http://www.julphar.net/index2.asp</ref><ref>http://www.planetpharmacyme.com/Planet-Pharmacy-About-Us.html</ref><ref>http://www.ameinfo.com/292183.html</ref><ref>http://www.jusline.ae/plant.htm</ref><ref>The National, nparmer@thenational.ae, March</ref>

2011, 32.6 million people are living with diabetes in the region, and this is expected to increase by over 80% by 2030 <ref>International Diabetes Federation - The IDF Diabetes Atlas Fifth Edition. Brussels:International Diabetes Federation; 2011</ref>

The insulin production plant (Julphar XI) is expected to widen its product offerings and strengthen its market presence in diabetic care. Since diabetes afflicts sizeable sections of the Middle East population, Julphar’s foray into bulk insulin production could not have been more timely. Julphar’s first insulin production began eight years ago when insulin crystals were imported from European sources for the local production of Jusline. Julphar invested $136.1 million in its new plant in Ras Al Khaimah.

Other Julphar subsidiaries include Menacool; a transportation division which maintains a fleet of XX vehicles, and Planet Pharmacies; a joint venture with Global Investment House which was established in 2007, and grew from the acquisition of independent pharmacy businesses located across the United Arab Emirates, the Sultanate of Oman and the Kingdom of Saudi Arabia. With an investment fund of over US $300 million, Planet Pharmacy has region-wide exclusive agency agreements with major international brands and an annual turnover of over US $100 million.<ref>http://www.planetpharmacyme.com/Planet-Pharmacy-About-Us.html</ref>

Julphar maintains a network of eleven manufacturing plants based in the UAE, with plans underway to open additional facilities in strategic countries such as Kingdom of Saudi Arabia, Ethiopia and Algeria. In 2011 Julphar signed an agreement with Saudi-based Cigalah Group, to build an independent manufacturing facility in the western region of KSA, in a project worth US$40 million.<ref>http://www.khaleejtimes.com/DisplayArticleNew.asp?section=business&xfile=data/business/2011/november/business_november455.xml</ref>
In 2011, Julphar crossed AED 1billion in sales for the first time, an 11.3% growth from 2010,<ref>The National, nparmer@thenational.ae, March 2012</ref> putting an international spotlight on Middle Eastern local companies and their plans for future growth and regional development.

In 2011, Julphar won the Arab Achievement Award. The award was organized by Global Business in collaboration with the Dubai Knowledge Village and was hosted during the 2nd Arab Conference for Investment in Abu Dhabi. The award highlights the importance of Julphar in the Middle East in providing quality pharmaceuticals through various important healthcare projects. Julphar provides annual funding and scholarships for local companies, such as the American University of Ras Al Khaimah.

{|
|-
| [[File:Julphar Building.jpg|thumb|[http://www.julphar.net/Vision%20of%20Incorporation.htm Julphar Building]]] || [[File:Julphar_Biotechnology_Lab.jpg |thumb|[http://www.julphar.net/JVII.htm Julphar Biotechnology Lab]]]
|}

==Board of Directors==

* [[Chairman of the Board]] (H.H. Sheikh Faisal Bin Saqr Al Qasimi)
* [[Vice-Chairman of the Board]] (H.E. Hassan Ahmed Al Alkim)
* [[Members of the Board]] (Sheikh Ahmed Bin Saqr Al Qasimi)
* [[Members of the Board]] (Sheikh Saqr Bin Humaid Al Qasimi)
* [[Members of the Board]] (Mr. Ahmed Essa Al Naem)
* [[Members of the Board]] (Mr. Nawaf Ghobash Ahmed Saeed)
* [[Members of the Board]] (Mr. Mohamed Jamaluddin Al Saati)
* [[Members of the Board]] (Dr. Ali Hussein Al Zawawi)
* [[Members of the Board]] (Mr. Ahmed Salim Al Hosni)
* [[Chief Executive Officer]] (Dr. Ayman Ahmed Sahli)[http://julphar.net/Board%20of%20Directors.htm ]


==Operations==
==Operations==
Julphar is a composite corporation with nine Drug Manufacturing facilities located in UAE.<ref>[http://www.julphar.net/JulpharGroup.htm# Julphar Plants]</ref>


{|
Julphar runs nine production facilities, where its entire range of pharmaceutical products are produced and packed. The nine facilities are devoted to nine different classes of products, together forming the core production facility of the company.
|-
| • [http://julphar.net/JI.htm Julphar I] (Pharmaceutical Solid Dosage Forms)
|-
| • [http://julphar.net/JII.htm Julphar II] (B-Lactam Antibiotics and Sterile Dosage Forms)
|-
| • [http://julphar.net/JIII.htm Julphar III] (Oral Penicillin Plant)
|-
| • [http://julphar.net/JIV.htm Julphar IV] (Oral Cephalosporin Plant)
|-
| • [http://julphar.net/JV.htm Julphar V] (Off-line Packaging Plant)
|-
| • [http://julphar.net/JVI.htm Julphar VI] (Liquid and Semi Solid Pharmaceutical Dosage Form)
|-
| • [http://julphar.net/JVII.htm Julphar VII] (Biotech Lab and Production Facility)
|-
| • [http://julphar.net/JVIII.htm Julphar VIII] (Sterile Powder Filling Plant)
|-
| • [http://julphar.net/JIX.htm Julphar IX] (Sterile Cephalosporin Powder Filling Plant)
|-
| • [http://julphar.net/JX.htm Julphar X] (Semi-solid plant)
|-
| • [http://julphar.net/JXI.htm Julphar X1] (Julphar Diabetes – Insulin Plant) <ref>http://julphar.net/JulpharGroup.htm</ref>
|}

{|
|-
| [[File:JulpharManufatureMedicine.jpg|thumb|[http://julphar.net/JulpharGroup.htm Julphar Plant]]] || [[File:JulpharInsulinPlant.jpg|thumb|Julphar Insulin Plant]]]
|}


* [[Julphar I]] (Pharmaceutical Solid dosage Forms)
* [[Julphar II]] (B-Lactam Antibiotics & Sterile Dosage Forms )
* [[Julphar III]] (Oral Penicillin Plant)
* [[Julphar IV]] (Oral Cephalosporin Plant)
* [[Julphar V]] (Off-line Packaging Plant)
* [[Julphar VI]] (Liquid & Semi Solid Pharmaceutical Dosage Form)
* [[Julphar VII]] (Biotech Lab and Production Facility)
* [[Julphar VIII]] (Sterile Powder Filling Plant)
* [[Julphar IX]] (Sterile Cephalosporin Powder Filling Plant)
* [[Julphar XI]] [[insulin]]<ref name="ab20120429" />
==Products==
==Products==
[http://julphar.net/Products.htm Julphar Products] <ref>http://julphar.net/Products.htm</ref>
Julphar has more than 800 formulations and 184 brands under its flag with products in
every major therapeutic category. Julphar’s product range includes Analgesics, Anti-Malarial, Anti-Biotic, Anti-Amoebic, Ankjkijio iuiu ii


{| class="wikitable sortable"
==Other locations==
|-
In 2009, Julphar launched sales and distribution in Senegal through distribution company Celphar. <ref>{{cite news
! Therapeutic category !! Product name
|url=http://fr.allafrica.com/stories/200907200952.html
|-
|title=Sénégal: Le groupe pharmaceutique Julphar s'implante au Sénégal - le traitement du diabète, de l'insuffisance rénale plus accessible
| Antibiotic || AQUABIOTICA
|last=Niang
|-
|first=Issa
| Antibiotic|| AZOMYCIN
|date=20 July 2009
|-
|publisher=AllAfrica
| Antibiotic|| CEFRIN
|language=French
|-
|accessdate=25 April 2012}}</ref> <ref>{{cite news
| Antibiotic|| CEFUZIME
|url=http://fr.allafrica.com/stories/200907210245.html
|-
|title=Sénégal: Lancement d'activités d'un nouveau Laboratoire pharmaceutique
| Antibiotic|| CEFUZIME-Inj
|date=20 July 2009
|-
|publisher=Agence de Presse Sénégalaise
| Antibiotic|| CLAMYCIN
|accessdate=25 April 2012}}</ref>
|-
| Antibiotic|| DURADOX
|-
| Antibiotic|| EROMYCIN
|-
| Antibiotic|| ESKACEF
|-
| Antibiotic|| GENTAL-INJ
|-
| Antibiotic|| JENOQUINE
|-
| Antibiotic|| JULMENTIN
|-
| Antibiotic|| JULPHAMOX
|-
| Antibiotic|| JULPHAPEN
|-
| Antibiotic|| LOMAX
|-
| Antibiotic|| MAXINEM
|-
| Antibiotic|| MIKACIN
|-
| Antibiotic|| MIRAN
|-
| Antibiotic|| NEGACEF
|-
| Antibiotic|| OXYTETRACYCLINE
|-
| Antibiotic|| Q-PIME
|-
| Antibiotic|| RECOCEF
|-
| Antibiotic|| RITHROCID
|-
| Antibiotic|| SARF
|-
| Antibiotic|| TETRACYCLINE
|-
| Antibiotic|| TRIAXONE
|-
| Antibiotic|| TRIMOL
|-
| Antibiotic|| UROXIN
|-
| Antibiotic|| VANCOLON
|-
| Biotech|| EPOTIN
|-
| Biotech|| FEROMAX
|-
| Biotech|| SIGMASPORIN
|-
| Cardiovascular|| AMIRONE
|-
| Cardiovascular|| AMLODIPINE
|-
| Cardiovascular|| CAPTOFAR
|-
| Cardiovascular|| CARDILOL
|-
| Cardiovascular|| CARDIOPINE
|-
| Cardiovascular|| FOSIPRIL
|-
| Cardiovascular|| INDANORM
|-
| Cardiovascular|| JUSPRIN
|-
| Cardiovascular|| LIPIGARD
|-
| Cardiovascular|| LIPITROL
|-
| Cardiovascular|| LISOTEC
|-
| Cardiovascular|| MEDOPA
|-
| Cardiovascular|| NARAPRIL
|-
| Cardiovascular|| SALURIN
|-
| Cardiovascular|| SIMVAST
|-
| Cardiovascular|| TENSOTIN
|-
| Cardiovascular|| TICOPAR
|-
| Cardiovascular|| Example
|-
| Dermatology|| ALFACORT
|-
| Dermatology|| BETASONE
|-
| Dermatology|| DEXIPAN
|-
| Dermatology|| FUTASOLE
|-
| Dermatology|| FUTASONE
|-
| Dermatology|| GAMAVATE
|-
| Dermatology|| GENTAL
|-
| Dermatology|| LOVRAK
|-
| Dermatology|| MIKOSTAT
|-
| Dermatology|| MIKOSTAT-Top
|-
| Dermatology|| MIKOZAL
|-
| Dermatology|| PANDERM
|-
| Dermatology|| PROSKIN
|-
| GIT|| ALBENDA
|-
| GIT|| ALINAL
|-
| GIT|| ALKASID
|-
| GIT|| CIMETAG
|-
| GIT|| DIZINIL
|-
| GIT|| FAMOTEC
|-
| GIT|| INTARD
|-
| GIT|| KAPTIN
|-
| GIT|| KAPTIN-II
|-
| GIT|| LANFAST
|-
| GIT|| LAXAL
|-
| GIT|| LAXOCODYL
|-
| GIT|| LAXOLYNE
|-
| GIT|| LIDOCAINE
|-
| GIT|| MEBZOL
|-
| GIT|| MODODOM
|-
| GIT|| NEGAZOLE
|-
| GIT|| PANTEC
|-
| GIT|| PREMOSAN
|-
| GIT|| PREMOSAN-inj
|-
| GIT|| RANTAG
|-
| GIT|| RISEK
|-
| GIT|| SALINAL
|-
| GIT|| SCOPINAL
|-
| GIT|| SOFLAX
|-
| GIT|| SUCRALOSE
|-
| GIT|| SUPRAPROCT
|-
| Insulin|| JUSLINE
|-
| Metabolic|| ANTIPROTIN
|-
| Metabolic|| DIALON
|-
| Metabolic|| DIAZIPAM
|-
| Metabolic|| ECOCAIN
|-
| Metabolic|| FITZCALM
|-
| Metabolic|| FLUTIN
|-
| Metabolic|| GLYNASE
|-
| Metabolic|| GLYPRIDE
|-
| Metabolic|| GLYZIDE
|-
| Metabolic|| TAMOPHAR
|-
| Metabolic|| VALOPIN
|-
| Over The Counter|| 3v
|-
| Over The Counter|| ACECLOFAR
|-
| Over The Counter|| ADOL
|-
| Over The Counter|| ADOL CO
|-
| Over The Counter|| ADOL PLUS
|-
| Over The Counter|| AMYDRAMINE
|-
| Over The Counter|| AMYDRAMINE-II
|-
| Over The Counter|| BCOOL
|-
| Over The Counter|| BECOVIT
|-
| Over The Counter|| CALVITALIS
|-
| Over The Counter|| CALYPTUS
|-
| Over The Counter|| CD-CAL
|-
| Over The Counter|| CLOFEN
|-
| Over The Counter|| CYNOVIT
|-
| Over The Counter|| GINSAVIT
|-
| Over The Counter|| JULMAG
|-
| Over The Counter|| JULVITALIS
|-
| Over The Counter|| KDIRON
|-
| Over The Counter|| MIXAVIT
|-
| Over The Counter|| MOXAL
|-
| Over The Counter|| MOXAL-II
|-
| Over The Counter|| MUCOLYTE
|-
| Over The Counter|| MUCUM
|-
| Over The Counter|| MUSCADOL
|-
| Over The Counter|| PROFINAL
|-
| Over The Counter|| PROFINAL-XP
|-
| Over The Counter|| PYRIDOXIN
|-
| Over The Counter|| ROTHACIN
|-
| Over The Counter|| RUBICALM
|-
| Over The Counter|| SOOLAN
|-
| Over The Counter|| THIAVIT
|-
| Over The Counter|| VIT C
|-
| Over The Counter|| VITA+D
|-
| Pulmonary|| ASMAFORT
|-
| Pulmonary|| ATROPULM
|-
| Pulmonary|| BECLOHALE
|-
| Pulmonary|| BUTALIN
|-
| Pulmonary|| BUTALIN-INH
|-
| Pulmonary|| CETRALON
|-
| Pulmonary|| CHLOROHISTOL
|-
| Pulmonary|| CODAPHED
|-
| Pulmonary|| EXEDEXE
|-
| Pulmonary|| FLUKIT
|-
| Pulmonary|| GUPISONE
|-
| Pulmonary|| HISTALOC
|-
| Pulmonary|| HISTOL
|-
| Pulmonary|| LORATIN
|-
| Pulmonary|| NASIVIN
|-
| Pulmonary|| NORMALINE
|-
| Pulmonary|| POTENCORT
|-
| Pulmonary|| SEDOFAN
|-
| Pulmonary|| SONIDAR
|-
| Pulmonary|| THEOFAR
|-
| Pulmonary|| XYLOLIN
|-
| Pulmonary|| ZORDYL
|-
| Women's Health|| FOLICRON
|-
| Women's Health|| FOLICUM
|-
| Women's Health|| GYNO-MIKOZAL
|-
| Women's Health|| ORAMAX
|-
| Wound and Burn|| MEBO
|-
| Wound and Burn|| MEBO-scar
|}


==References==
==References==
{{Reflist}}
{{Reflist}}


*[http://julphar.net/Products/annual%20report%202008%20english.pdf Annual Report 2008 (8.10 MB PDF, English Version)]
[http://www.julphar.net/annual%20report%202010/index.html Annual Report 2010 (9.47 MB PDF, English and Arabic Version)]
*[http://julphar.net/Products/2008%20Arabic%20Annaul%20Report.pdf Annual Report 2008 (4 MB PDF, Arabic Version)]


[http://julphar.net/Products/English%20annual%20report%202009.pdf Annual Report 2009 (4.62 MB PDF, English Version)]
==External links==
* {{Official website|http://www.julphar.net/}}


[http://julphar.net/Products/annual%20report%202009%20arabic.pdf Annual Report 2009 (6.79 MB PDF, Arabic Version)]

[http://julphar.net/Products/annual%20report%202008%20english.pdf Annual Report 2008 (8.10 MB PDF, English Version)]

[http://julphar.net/Products/2008%20Arabic%20Annaul%20Report.pdf Annual Report 2008 (4 MB PDF, Arabic Version)]

==External links==
* [http://www.julphar.net www.julphar.net]
* [http://www.planetpharmacyme.com www.planetpharmacyme.com]
* http://www.idf.org
[[Category: List of companies of the United Arab Emirates]]


[[Category:Pharmaceutical companies]]
[[Category: List of pharmaceutical companies]]
[[Category:Companies of the United Arab Emirates]]

Revision as of 10:50, 6 May 2012

Gulf Pharmaceutical Industries (Julphar)
Company typePublic
IndustryPharmaceutical
Founded1980
HeadquartersRAK, UAE
Key people
Sheikh Faisal bin Saqr Al Qasimi Chairman of the Board
Dr. Ayman Ahmed Sahli Chief Executive Officer's
ProductsJulphar manufacture and sell more than 423 Products
RevenueIncrease AED 1,024.1 Billion (2011)
Increase AED 200.0 Million (2011)
Increase AED 170.2 Million (2011)
Number of employees
circa 1740
Websitewww.julphar.net

About

Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company based in Ras Al Khaimah, United Arab Emirates. It was established in 1980 under H.H Sheikh Saqr Bin Mohammed Al Qasimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents. With 3537 products registered (as of February 20, 2012), it is recognized as one of the largest pharmaceutical manufacturers of generic drugs in the Middle East. Julphar manages a diverse portfolio of therapeutic products which targets a large range of major pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology. (see Products) One of Julphar’s strategic products include Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. Cosmetic scar therapy is a lucrative business worldwide and MEBO Scar follows the success of MEBO, a widely distributed wound healing product. The release of MEBO Scar will help patients with both functional and cosmetic problems caused by scarring and improve their quality of life.[1]

In 2012, Julphar will become the only company in the Middle East and North Africa Region to locally produce r- DNA, the raw material used to make insulin. Julphar Diabetes – a division of Julphar that will manage the manufacturing and commercialization the company’s diabetes products, has the facility capabilities to produce approximately 40 million vials of insulin per year. This makes Julphar the 5th largest producer of insulin in the world, and the only one in the Middle East. In 2011, Julphar signed a partnership with International Diabetes Federation (IDF), ensuring IDF has a key partner in the Middle East region in the fight against diabetes and in their efforts to promote better diabetes care, management and education. Diabetes rates in the MENA are amongst the highest in the world. IDF estimates that in [2][3][4][5][6]

2011, 32.6 million people are living with diabetes in the region, and this is expected to increase by over 80% by 2030 [7]

The insulin production plant (Julphar XI) is expected to widen its product offerings and strengthen its market presence in diabetic care. Since diabetes afflicts sizeable sections of the Middle East population, Julphar’s foray into bulk insulin production could not have been more timely. Julphar’s first insulin production began eight years ago when insulin crystals were imported from European sources for the local production of Jusline. Julphar invested $136.1 million in its new plant in Ras Al Khaimah.

Other Julphar subsidiaries include Menacool; a transportation division which maintains a fleet of XX vehicles, and Planet Pharmacies; a joint venture with Global Investment House which was established in 2007, and grew from the acquisition of independent pharmacy businesses located across the United Arab Emirates, the Sultanate of Oman and the Kingdom of Saudi Arabia. With an investment fund of over US $300 million, Planet Pharmacy has region-wide exclusive agency agreements with major international brands and an annual turnover of over US $100 million.[8]

Julphar maintains a network of eleven manufacturing plants based in the UAE, with plans underway to open additional facilities in strategic countries such as Kingdom of Saudi Arabia, Ethiopia and Algeria. In 2011 Julphar signed an agreement with Saudi-based Cigalah Group, to build an independent manufacturing facility in the western region of KSA, in a project worth US$40 million.[9]

In 2011, Julphar crossed AED 1billion in sales for the first time, an 11.3% growth from 2010,[10] putting an international spotlight on Middle Eastern local companies and their plans for future growth and regional development.

In 2011, Julphar won the Arab Achievement Award. The award was organized by Global Business in collaboration with the Dubai Knowledge Village and was hosted during the 2nd Arab Conference for Investment in Abu Dhabi. The award highlights the importance of Julphar in the Middle East in providing quality pharmaceuticals through various important healthcare projects. Julphar provides annual funding and scholarships for local companies, such as the American University of Ras Al Khaimah.

File:Julphar Building.jpg
Julphar Building
File:Julphar Biotechnology Lab.jpg
Julphar Biotechnology Lab

Board of Directors

Operations

• Julphar I (Pharmaceutical Solid Dosage Forms)
• Julphar II (B-Lactam Antibiotics and Sterile Dosage Forms)
• Julphar III (Oral Penicillin Plant)
• Julphar IV (Oral Cephalosporin Plant)
• Julphar V (Off-line Packaging Plant)
• Julphar VI (Liquid and Semi Solid Pharmaceutical Dosage Form)
• Julphar VII (Biotech Lab and Production Facility)
• Julphar VIII (Sterile Powder Filling Plant)
• Julphar IX (Sterile Cephalosporin Powder Filling Plant)
• Julphar X (Semi-solid plant)
• Julphar X1 (Julphar Diabetes – Insulin Plant) [11]
File:JulpharManufatureMedicine.jpg
Julphar Plant
File:JulpharInsulinPlant.jpg
Julphar Insulin Plant
]

Products

Julphar Products [12]

Therapeutic category Product name
Antibiotic AQUABIOTICA
Antibiotic AZOMYCIN
Antibiotic CEFRIN
Antibiotic CEFUZIME
Antibiotic CEFUZIME-Inj
Antibiotic CLAMYCIN
Antibiotic DURADOX
Antibiotic EROMYCIN
Antibiotic ESKACEF
Antibiotic GENTAL-INJ
Antibiotic JENOQUINE
Antibiotic JULMENTIN
Antibiotic JULPHAMOX
Antibiotic JULPHAPEN
Antibiotic LOMAX
Antibiotic MAXINEM
Antibiotic MIKACIN
Antibiotic MIRAN
Antibiotic NEGACEF
Antibiotic OXYTETRACYCLINE
Antibiotic Q-PIME
Antibiotic RECOCEF
Antibiotic RITHROCID
Antibiotic SARF
Antibiotic TETRACYCLINE
Antibiotic TRIAXONE
Antibiotic TRIMOL
Antibiotic UROXIN
Antibiotic VANCOLON
Biotech EPOTIN
Biotech FEROMAX
Biotech SIGMASPORIN
Cardiovascular AMIRONE
Cardiovascular AMLODIPINE
Cardiovascular CAPTOFAR
Cardiovascular CARDILOL
Cardiovascular CARDIOPINE
Cardiovascular FOSIPRIL
Cardiovascular INDANORM
Cardiovascular JUSPRIN
Cardiovascular LIPIGARD
Cardiovascular LIPITROL
Cardiovascular LISOTEC
Cardiovascular MEDOPA
Cardiovascular NARAPRIL
Cardiovascular SALURIN
Cardiovascular SIMVAST
Cardiovascular TENSOTIN
Cardiovascular TICOPAR
Cardiovascular Example
Dermatology ALFACORT
Dermatology BETASONE
Dermatology DEXIPAN
Dermatology FUTASOLE
Dermatology FUTASONE
Dermatology GAMAVATE
Dermatology GENTAL
Dermatology LOVRAK
Dermatology MIKOSTAT
Dermatology MIKOSTAT-Top
Dermatology MIKOZAL
Dermatology PANDERM
Dermatology PROSKIN
GIT ALBENDA
GIT ALINAL
GIT ALKASID
GIT CIMETAG
GIT DIZINIL
GIT FAMOTEC
GIT INTARD
GIT KAPTIN
GIT KAPTIN-II
GIT LANFAST
GIT LAXAL
GIT LAXOCODYL
GIT LAXOLYNE
GIT LIDOCAINE
GIT MEBZOL
GIT MODODOM
GIT NEGAZOLE
GIT PANTEC
GIT PREMOSAN
GIT PREMOSAN-inj
GIT RANTAG
GIT RISEK
GIT SALINAL
GIT SCOPINAL
GIT SOFLAX
GIT SUCRALOSE
GIT SUPRAPROCT
Insulin JUSLINE
Metabolic ANTIPROTIN
Metabolic DIALON
Metabolic DIAZIPAM
Metabolic ECOCAIN
Metabolic FITZCALM
Metabolic FLUTIN
Metabolic GLYNASE
Metabolic GLYPRIDE
Metabolic GLYZIDE
Metabolic TAMOPHAR
Metabolic VALOPIN
Over The Counter 3v
Over The Counter ACECLOFAR
Over The Counter ADOL
Over The Counter ADOL CO
Over The Counter ADOL PLUS
Over The Counter AMYDRAMINE
Over The Counter AMYDRAMINE-II
Over The Counter BCOOL
Over The Counter BECOVIT
Over The Counter CALVITALIS
Over The Counter CALYPTUS
Over The Counter CD-CAL
Over The Counter CLOFEN
Over The Counter CYNOVIT
Over The Counter GINSAVIT
Over The Counter JULMAG
Over The Counter JULVITALIS
Over The Counter KDIRON
Over The Counter MIXAVIT
Over The Counter MOXAL
Over The Counter MOXAL-II
Over The Counter MUCOLYTE
Over The Counter MUCUM
Over The Counter MUSCADOL
Over The Counter PROFINAL
Over The Counter PROFINAL-XP
Over The Counter PYRIDOXIN
Over The Counter ROTHACIN
Over The Counter RUBICALM
Over The Counter SOOLAN
Over The Counter THIAVIT
Over The Counter VIT C
Over The Counter VITA+D
Pulmonary ASMAFORT
Pulmonary ATROPULM
Pulmonary BECLOHALE
Pulmonary BUTALIN
Pulmonary BUTALIN-INH
Pulmonary CETRALON
Pulmonary CHLOROHISTOL
Pulmonary CODAPHED
Pulmonary EXEDEXE
Pulmonary FLUKIT
Pulmonary GUPISONE
Pulmonary HISTALOC
Pulmonary HISTOL
Pulmonary LORATIN
Pulmonary NASIVIN
Pulmonary NORMALINE
Pulmonary POTENCORT
Pulmonary SEDOFAN
Pulmonary SONIDAR
Pulmonary THEOFAR
Pulmonary XYLOLIN
Pulmonary ZORDYL
Women's Health FOLICRON
Women's Health FOLICUM
Women's Health GYNO-MIKOZAL
Women's Health ORAMAX
Wound and Burn MEBO
Wound and Burn MEBO-scar

References

  1. ^ http://www.ameinfo.com/292183.html
  2. ^ http://www.julphar.net/index2.asp
  3. ^ http://www.planetpharmacyme.com/Planet-Pharmacy-About-Us.html
  4. ^ http://www.ameinfo.com/292183.html
  5. ^ http://www.jusline.ae/plant.htm
  6. ^ The National, nparmer@thenational.ae, March
  7. ^ International Diabetes Federation - The IDF Diabetes Atlas Fifth Edition. Brussels:International Diabetes Federation; 2011
  8. ^ http://www.planetpharmacyme.com/Planet-Pharmacy-About-Us.html
  9. ^ http://www.khaleejtimes.com/DisplayArticleNew.asp?section=business&xfile=data/business/2011/november/business_november455.xml
  10. ^ The National, nparmer@thenational.ae, March 2012
  11. ^ http://julphar.net/JulpharGroup.htm
  12. ^ http://julphar.net/Products.htm

Annual Report 2010 (9.47 MB PDF, English and Arabic Version)

Annual Report 2009 (4.62 MB PDF, English Version)

Annual Report 2009 (6.79 MB PDF, Arabic Version)

Annual Report 2008 (8.10 MB PDF, English Version)

Annual Report 2008 (4 MB PDF, Arabic Version)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Julphar&oldid=490963019"